Press release
Lawsuit filed for Investors in ImmunityBio, Inc. (NASDAQ: IBRX) in effort to recover losses
A lawsuit was filed on behalf of investors in ImmunityBio, Inc. (NASDAQ: IBRX) shares over alleged securities laws violations.
Investors who purchased shares of ImmunityBio, Inc. (NASDAQ: IBRX) have certain options and for certain investors are short and strict deadlines running. Deadline: August 29, 2023. NASDAQ: IBRX investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
San Diego, CA based ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases in the United States and Europe.
On May 11, 2023, Reuters reported that the U.S. Food and Drug Administration declined to approve I ImmunityBio, Inc's combination therapy to treat a type of bladder cancer due to deficiencies in its application. The Company also reiterated doubts about its ability to remain in business in a filing with the Securities and Exchange Commission.
Shares of ImmunityBio, Inc. (NASDAQ: IBRX) declined from $6.93 per share on May 09, 2023, to $2.25 per share on May 15, 2023.
The plaintiff claims that between May 23, 2022 and May 10, 2023, the Defendants made false and/or misleading statements and/or failed to disclose that ImmunityBio conducted insufficient due diligence to discover, or else did discover and ignored, GMP deficiencies at its third-party CMOs for Anktiva, that one or more of the Company's third-party CMOs for Anktiva did in fact suffer from GMP deficiencies, that the foregoing deficiencies was likely to cause the FDA to reject the Anktiva BLA in its present form, that accordingly, the Company overstated the regulatory approval prospects for the Anktiva BLA, and that as a result, the Company's public statements were materially false and misleading at all relevant times.
Those who purchased shares of ImmunityBio, Inc. (NASDAQ: IBRX) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lawsuit filed for Investors in ImmunityBio, Inc. (NASDAQ: IBRX) in effort to recover losses here
News-ID: 3155955 • Views: …
More Releases from Shareholders Foundation
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made.
If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have…
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp.
Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for ImmunityBio
Natural Killer Cell Therapies Clinical Trials, Companies, Therapeutic Assessment …
DelveInsight's, "Natural Killer Cell Therapies - Pipeline Insight, 2025," report provides comprehensive insights about 100+ companies and 140+ pipeline drugs in Natural Killer Cell Therapies pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
DelveInsight reports that over 100 key…
Nk Cell Therapy Clinical Trials, Companies, Therapeutic Assessment, Therapies, T …
DelveInsight's, "NK Cell Therapies Pipeline Insight, 2025" report provides comprehensive insights about 140+ companies and 160+ pipeline drugs in NK Cell Therapies pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Nk Cell Therapy Pipeline constitutes 140+ key companies continuously…
Natural Killer (NK)-Cell Lymphoma Market to Expand Significantly by 2032, States …
The Key Natural Killer (NK)-Cell Lymphoma Companies in the market include - Innate Pharma, Nektar Therapeutics, ImmunityBio, CytoVac, Celularity, and others.
DelveInsight's "Natural Killer (NK)-Cell Lymphoma Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Natural Killer (NK)-Cell Lymphoma, historical and forecasted epidemiology as well as the Natural Killer (NK)-Cell Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To…
NK Cell Therapy Pipeline Outlook Report 2024 (Updated) | ImmunityBio, Cantargia, …
DelveInsight's, "NK Cell Therapy Pipeline Insight 2024" report provides comprehensive insights about 100+ companies and 185+ pipeline drugs in NK Cell Therapy pipeline landscape. It covers the NK Cell Therapy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NK Cell Therapy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key…
Bladder Cancer Pipeline Outlook Report 2024 | CG Oncology, ImmunityBio, UroGen, …
DelveInsight's, "Bladder Cancer Pipeline Insight 2024" report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in the Bladder cancer pipeline landscape. It covers the Bladder Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bladder Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the…
Investigation announced for Long-Term Investors in shares of ImmunityBio, Inc. ( …
An investigation was announced for current long-term investors in shares of ImmunityBio, Inc. (NASDAQ: IBRX) concerning potential breaches of fiduciary duties by certain directors of ImmunityBio, Inc.
Investors who are current long term investors in ImmunityBio, Inc. (NASDAQ: IBRX) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors NASDAQ: IBRX stocks follows…
